我院FOLFOX4方案治疗胃肠道肿瘤致54例次不良反应分析  

Analysis of 54 Cases of ADR Caused by FOLFOX4 Chemotherapy Regimen for Gastrointestinal Tumors in China

作　　者：邓玉琴[1] 陆超[1] 何光照[1] 张明珠[1] 罗卓卡[1] 

机构地区：[1]苏州大学附属常州肿瘤医院,江苏常州213001

出　　处：《中国药房》2014年第12期1113-1115,共3页China Pharmacy

摘　　要：目的:探讨FOLFOX4方案治疗胃肠道肿瘤致不良反应(ADR)的特点,为临床安全使用FOLFOX4方案化疗提供科学依据。方法:回顾性统计和分析予FOLFOX4方案治疗胃癌、结直肠癌患者致54例次ADR的相关情况。结果:54例次ADR中,患者中位年龄53岁;ADR关联性评价为肯定的4例次、很可能的20例次、可能的30例次;以血液系统损害最多见;一般ADR 33例次,严重ADR 21例次,其中严重ADR有:白细胞计数减少9例次,血小板计数减少5例次,过敏反应4例次,瘙痒症3例次;所有ADR经相应处理后均得以好转或恢复正常。结论:FOLFOX4方案治疗胃肠道肿瘤可能出现多种ADR,临床需要掌握相关ADR的特点,及时采取相应的预防和治疗措施,以减少ADR导致的危害。OBJECTIVE： To provide scientific reference for clinical safe use of FOLFOX4 regimen through analyzing clinical feature of adverse drug reaction （ADR） caused by FOLFOX4 chemotherapy regimen for gastrointestinal tumors. METHODS： 54 cases of ADR caused by FOLFOX4 regimen for gastric, colon and rectum cancer were analyzed retrospectively. RESULTS： Among 54 ADR cases, the age of patients was 53 in average; there were 4 cases of defmite relevance, 20 cases of probable relevance and 30 cases of possible relevance. The commonest injury was hematological system injury. There were 33 cases of common ADR and 21 cases of severe ADR; severe ADR included 9 cases of leukopenia, 5 cases of thrombocytopenia, 4 cases of anaphylactic reaction and 3 cases of pruritus. All ADRs were improved or cured after treatment. CONCLUSIONS： A variety of ADRs might occur with FOLFOX4 regimen in the treatment of gastrointestinal tumors. Clinical features of ADR need to be mastered and appropriate preventive and therapeutic measures should be taken to reduce the injury caused by ADRs.

关 键 词：FOLFOX4方案 胃肠道肿瘤 不良反应 

分 类 号：R735[医药卫生—肿瘤] R969.3[医药卫生—临床医学]